Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.

For subclonal mutations, all our observations remained significant (anti-EGFR, β = 9.86, P = 6.23 × 10 −05 ; DNA repair, β = 11.41, P = 2.94 × 10 −06 ; length of time on cytotoxic agents, β = 0.28, P = 0.0027), and there was a negative trend for the time between samples ( β = −0.15, P = 0.0027).

also in 925 other papers

There is limited literature surrounding CHIP and ICI response in solid tumors; however, a study reported a longer time on PD1/PDL1 agents for non–small cell lung cancer and melanoma patients with DNMT3A mutations (21 cycles; range, 10–40) compared with patients with wild-type DNMT3A (7 cycles, range, 1–13), although a small sample size meant that this did not reach statistical significance ( 31 ).

also in 17,681 other papers